32 results on '"Soini, EJ"'
Search Results
2. PHP226 - Comorbidity-Based Eq-5d Scores Of Primary Care Patients In Finland, Their Potential To Benefit And Unmet Medical Need
3. PHP184 - Health-Related Quality Of Life (Hrqol) Based On Preferences From 14 Countries In Primary Health Care Setting (Phcs)
4. PND15 - Disease Modifying Treatment (Dmt) is Associated with Lower Hazard for Death Among Multiple Sclerosis (Ms) Patients: Survival Analysis Based on 30 Years Incident Ms Cohort
5. PRM191 - Watch Out for Berkson's Bias (BB)! Setting Health-Related Quality of Life (HRQOL) Treatment Targets with Matching-Adjusted Indirect Comparison (MAIC) in Order to Predict Matched General Population Control (MGPC) Targets, Assess Potential to Benefit (PTB) and Reveal Unmet Medical Need (UMN)
6. PMS43 COST-UTILITY AND MULTINOMIAL EXPECTED VALUE OF PERFECT INFORMATION OF SEQUENCED TREATMENT WITH BIOLOGICS IN MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: ANALYSIS BASED ON CLINICALLY MEANINGFUL RESPONSES
7. PR3 THE IMPACT OF FINNISH PHARMACEUTICAL PRICING SCHEME IN COST-EFFECTIVENESS ANALYSES
8. BL1 COST-EFFECTIVENESS, VALUE OF INFORMATION, AND BUDGET IMPACT OF CERTOLIZUMAB PEGOL COMPARED TO SUBCUTANEOUS TUMOR NECROSIS FACTOR (TNF) INHIBITORS AND METHOTREXATE IN THE TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS IN FINLAND
9. PCN105 ECONOMIC EVALUATION OF TRABECTEDIN IN THE TREATMENT OF METASTATIC SOFT-TISSUE SARCOMA (MSTS) IN THE FINNISH SETTING
10. PHP2 PREDICTING PERSISTENT FREQUENT USE OF THE PRIMARY HEALTH CARE SERVICES IN A FINNISH SETTING: A BAYESIAN APPROACH
11. PMS58 COST-UTILITY ANALYSIS OF DIFFERENT TREATMENT STRATEGIES AFTER THE FAILURE OF FIRST BIOLOGIC TREATMENT IN RHEUMATOID ARTHRITIS (RA) IN THE FINNISH SETTING
12. PIN80 THE ROLE OF ECONOMIC EVALUATION IN THE HEALTH TECHNOLOGY ASSESSMENT (HTA) OF VACCINES—LESSONS LEARNED FROM FINLAND
13. PND9 COST-EFFECTIVENESS AND BUDGET IMPACT MODELLING OF LACOSAMIDE IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN FINLAND
14. PMH45 COST-UTILITY OF AGOMELATINE, VENLAFAXINE AND PLACEBO IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN FINLAND—ECONOMIC MODELLING STUDY USING REPRESENTATIVE POPULATION DATA
15. PCV117 COST-UTILITY OF BOSENTAN IN THE FIRST-LINE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN FINLAND—A DISCRETE EVENT SIMULATION MODELLING
16. PMC23 WHAT IS POLITICIAN'S AND CLINICIAN'S WILLINGNESS TO PAY (WTP) FOR FUTURE HEALTH BENEFIT BASED ON 15D, EQ-5D AND LIFE-YEARS? A CONTINGENTVALUATION (CV) AMONG 8 DISEASES WITH THE TOTAL OF 1092 CASES
17. PCN35 ECONOMIC EVALUATION OF CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (CHOP) CHEMOTHERAPY REGIME WITH OR WITHOUT RITUXIMAB (R) IN THE 2ND LINE TREATMENT OF FOLLICULAR NON-HODGIN LYMPHOMA
18. PRS12 COST-EFFECTIVENESS ANALYSIS OF SYMBICORT SMART® VERSUS FIXED COMBINATION TREATMENTS IN FINLAND
19. PCV114 SEARCHING THE OPTIMAL TREATMENT MIX STRATEGY WITH A TREATMENT MIX CHART APPROACH—THE CASE OF CHOLESTEROL LOWERING IN SWEDEN
20. PIN22 - Health Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine In Finnish Home Care Customers ≥50 Years With Underlying Chronic Medical Conditions
21. PND44 - Cost-Effectiveness of First-Line Disease-Modifying Therapies (Dmts) For Relapsing-Remitting Ms (Rrms)
22. PSY65 - Cost-Effectiveness of Ustekinumab In The Treatment of Psoriasis In Finland
23. PHM5 ADVATE IS COST-EFFECTIVE INVESTMENT IN HEMOPHILIA A TREATMENT WHEN PATHOGENS EMERGE—A SCENARIO-BASED ECONOMIC AND POSITIVE INVESTMENT INTERVAL (Pll) EVALUATION
24. PCV72 EMPIRICAL EVALUATION OF THE PREDICTIVE PERFORMANCE OF CLASSIFICATION TOOLS IN CORONARY HEART DISEASE—P-COURSE, A NAIVE BAYES TOOL, OUTPERFORMS NOVEL LOGISTIC REGRESSION APPROACHES
25. PCV70 MULTINOMIAL PROPENSITY SCORE ESTIMATORS AND MULTIVARIATE EXPLANATORYTECHNIQUES IN A REAL-LIFE ACUTE CORONARY HEART DISEASE STUDY—THE QALYS AND COSTS OF MEDICATION, PTCAAND CABG TREATMENT MODALITY ARE HIGHLY DEPENDENT ON THE METHODS USED
26. PCN48 SUNITINIB MALATE PROVIDES ADDITIONAL SURVIVAL AND VALUE FOR MONEY AS A SECOND LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)—AN ECONOMIC EVALUATION USING BAYESIAN APPROACH
27. PHM15 POSITIVE INVESTMENT INTERVAL (PII)AND PAYBACK PERIOD (PP) OFFER DIFFERENT INTERPRETATIONS IN HEALTH TECHNOLOGY INVESTMENT DECISIONS: Pll ISA MATTER OF BEING AND PP IS A MATTER OF TURNING BENEFICIAL—A CASE OF HEMOPHILIA A
28. PSU2 ECONOMIC EVALUATION COMPARING FROM HOME TO OPERATION AND CONVENTIONAL PROCESS OF LAPAROSCOPIC CHOLECYSTECTOMY: PROSPECTIVE RANDOMIZED CONTROLLED TRIAL
29. PMH23 PREDICTING VIOLENT OFFENDING AMONG MENTALLY ILL IN A MULTINATIONAL SETTING–NAIVE BAYESIAN FUSION AND MODEL MERGING WITH P-COURSE
30. PMC4 PRESENTING IGNORANCE: A POSSIBILITY INTERVAL APPROACH TO DEPICT HIGH-LEVEL UNCERTAINTY DUE TO CENSORING OR NON-RESPONDENTS
31. PMC2 EFFICIENT DATA MINING AND PROBABILISTIC INFERENCE WITH P-COURSE: A BAYESIAN METHOD WITH MULTILEVEL PRIORS FOR MEDICAL APPLICATIONS
32. MC2 15DS-A NEW DYNAMIC QUALITY OF LIFE TOOL WITH INCREASED SENSITIVITY AND IMPROVED COMPOSITE STRUCTURE FOR RECALL BIAS AND RESPONSE SIFT ADJUSTMENTS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.